These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 3261814)
1. Adoptive immunotherapy in tumor-bearing mice with OK-432-induced killer cells. Ujiie T Jpn J Exp Med; 1988 Apr; 58(2):109-14. PubMed ID: 3261814 [TBL] [Abstract][Full Text] [Related]
2. Adoptive immunotherapy by pantropic killer cells recovered from OK-432-injected tumor sites in mice. Saito M; Nanjo M; Kataoka M; Moriya Y; Sugawara Y; Yoshida T; Ishida N Cancer Res; 1988 Aug; 48(15):4163-7. PubMed ID: 3390809 [TBL] [Abstract][Full Text] [Related]
3. Augmentation by OK-432 of generation of culture-induced killer cells. Ujiie T Jpn J Exp Med; 1987 Jun; 57(3):153-61. PubMed ID: 3682231 [TBL] [Abstract][Full Text] [Related]
4. [Successful adoptive immunotherapy with OK432-inducible activated natural killer cells on tumor-bearing mice]. Yamaue H; Tanimura H; Iwahashi M; Tani M; Tsunoda T; Tabuse K Nihon Gan Chiryo Gakkai Shi; 1989 Dec; 24(11):2546-55. PubMed ID: 2614190 [TBL] [Abstract][Full Text] [Related]
5. [Combined effect of intraperitoneally administered OK-432 and recombinant interleukin (rIL-2) against mouse tumors]. Fujioka T; Shiraishi M; Tanji S; Koike H; Kumagai K; Kubo T; Ohhori T Nihon Gan Chiryo Gakkai Shi; 1989 May; 24(5):948-56. PubMed ID: 2789265 [TBL] [Abstract][Full Text] [Related]
6. Enhanced generation of OK-432-induced killer cells by interleukin 2. Ujiie T Jpn J Exp Med; 1987 Jun; 57(3):183-8. PubMed ID: 3500332 [TBL] [Abstract][Full Text] [Related]
7. [Effect of combined immunotherapy using two different BRMs; OK-432 and IL-2-cultured lymphocytes]. Kan N; Hori T; Ohgaki K; Inamoto T; Kodama H; Tobe T Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1298-306. PubMed ID: 3488027 [TBL] [Abstract][Full Text] [Related]
8. Synergistic therapeutic effect of combination therapy with OK-432 and interferon-alpha or -gamma on Meth-A ascites tumor in BALB/c mice. Mizushima Y; Morikage T; Hirata H; Sato M; Sakamoto K; Yano S J Biol Response Mod; 1988 Aug; 7(4):371-83. PubMed ID: 3139841 [TBL] [Abstract][Full Text] [Related]
9. Distinct antitumor mechanisms of recombinant interleukin-2 on recombinant interleukin-2-activated killer-sensitive and -resistant murine tumors. Maekawa R; Kitagawa T; Koizumi K; Sato K; Homma M J Biol Response Mod; 1989 Dec; 8(6):676-90. PubMed ID: 2600605 [TBL] [Abstract][Full Text] [Related]
10. [Experimental and clinical study of adoptive immunotherapy combined with preadministration of OK-432: a method to augment the therapeutic effect]. Kan N; Okino T; Nakanishi M; Sato K; Mise K; Teramura Y; Yamasaki S; Hori T; Ohgaki K; Tobe T Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1455-61. PubMed ID: 2786379 [TBL] [Abstract][Full Text] [Related]
11. [Adoptive immunotherapy of murine tumors using cultured syngeneic tumor-bearer-spleen cells. II: Therapeutic effect of cultured lymphocytes against malignant ascites and its augmentation by the streptococcal preparation, OK 432]. Kan N; Inamoto T; Hori T; Nio Y; Tsuchitani T; Kodama H; Tobe T; Ohgaki K Nihon Gan Chiryo Gakkai Shi; 1985 May; 20(4):784-96. PubMed ID: 3877129 [No Abstract] [Full Text] [Related]
12. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types. Papa MZ; Mulé JJ; Rosenberg SA Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517 [TBL] [Abstract][Full Text] [Related]
13. [Induction of LAK cells in peritoneal cavity of mice after ip injection of OK-432 and antitumor effect of these LAK cells]. Ishida N; Saito M; Nanjo M Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2681-90. PubMed ID: 6508321 [TBL] [Abstract][Full Text] [Related]
14. Augmentation of mouse natural killer cell activity by a streptococcal preparation, OK-432. Oshimi K; Kano S; Takaku F; Okumura K J Natl Cancer Inst; 1980 Dec; 65(6):1265-9. PubMed ID: 7001124 [TBL] [Abstract][Full Text] [Related]
15. [Anticancer effects of OK-432 (2). Anticancer actions of M phi activated by OK-432]. Saito M; Aonuma E; Noda T; Nakadate I; Nanjo M; Ebina T; Ishida N Gan To Kagaku Ryoho; 1983 May; 10(5):1363-71. PubMed ID: 6870302 [TBL] [Abstract][Full Text] [Related]
16. Local adoptive immunotherapy of human head and neck cancer xenografts in nude mice with lymphokine-activated killer cells and interleukin 2. Sacchi M; Snyderman CH; Heo DS; Johnson JT; d'Amico F; Herberman RB; Whiteside TL Cancer Res; 1990 May; 50(10):3113-8. PubMed ID: 2334906 [TBL] [Abstract][Full Text] [Related]
17. [Role of the spleen in OK-432 immunotherapy and characterization of effector cells]. Yamagishi H; Naito K; Maeda Y; Kobayashi M; Kurioka H; Fujimori C; Tanaka T; Hashimoto I Gan To Kagaku Ryoho; 1983 Jul; 10(7):1670-8. PubMed ID: 6870309 [TBL] [Abstract][Full Text] [Related]
18. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. Spiess PJ; Yang JC; Rosenberg SA J Natl Cancer Inst; 1987 Nov; 79(5):1067-75. PubMed ID: 3500355 [TBL] [Abstract][Full Text] [Related]
19. [Immunobiological studies of interferon-alpha A/D in comparison with a streptococcal preparation, OK-432]. Mizushima Y; Hirata H; Sakamoto K; Sato M; Morikage T; Maruyama M; Sasaki K; Yano S Gan To Kagaku Ryoho; 1987 Sep; 14(9):2710-5. PubMed ID: 3631971 [TBL] [Abstract][Full Text] [Related]
20. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice. Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]